Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
•
Vaccines
•
Travel and Tropical Medicine
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
Related Questions
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
Do you have to extend treatment for acute Lyme disease if a patient is on high dose steroids for another indication?
What are your vaccine recommendations while patients are on biologics?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
